Lung cancer survival and comorbidities in lung cancer screening participants of the Gdańsk screening cohort.


Journal

European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966

Informations de publication

Date de publication:
01 12 2019
Historique:
pubmed: 21 4 2019
medline: 31 10 2020
entrez: 21 4 2019
Statut: ppublish

Résumé

In 2010, the World Health Organisation recommended implementation of screening programmes in four groups of diseases-neoplasms, cardiovascular diseases (CVD), diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD). It is due to the fact that they share the same, modifiable risk factors. Between 2009 and 2011, 8637 heavy smokers (aged 50-75, smoking history >20 pack-years) were screened in the Pomeranian Pilot Lung Cancer Screening Programme (PPP) in Gdańsk, Poland. We looked at 5-year follow-up and analysed the medical events and comorbidities of all participants. One health care provider in the Polish health care system provides a unique opportunity to gather most reliable data on all medical events in each person. In 52.0% of lung cancer screening participants CVD (33.5%), DM (26.0%) and COPD (21.0%) were diagnosed. Prevalence of these diseases is higher in lung cancer patients than in the non-cancer screening group (P < 0.0001). One hundred and seven (1.2%) lung cancers were diagnosed during PPP programme performance and another 382 cases (4.4%) in the 5-year follow-up, so the potential mean annual lung cancer detection rate is 0.77%. Lung cancer screening programme offers a great potential for joint screening of lung cancer, CVD, diabetes and COPD.

Sections du résumé

BACKGROUND
In 2010, the World Health Organisation recommended implementation of screening programmes in four groups of diseases-neoplasms, cardiovascular diseases (CVD), diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD). It is due to the fact that they share the same, modifiable risk factors.
METHODS
Between 2009 and 2011, 8637 heavy smokers (aged 50-75, smoking history >20 pack-years) were screened in the Pomeranian Pilot Lung Cancer Screening Programme (PPP) in Gdańsk, Poland. We looked at 5-year follow-up and analysed the medical events and comorbidities of all participants. One health care provider in the Polish health care system provides a unique opportunity to gather most reliable data on all medical events in each person.
RESULTS
In 52.0% of lung cancer screening participants CVD (33.5%), DM (26.0%) and COPD (21.0%) were diagnosed. Prevalence of these diseases is higher in lung cancer patients than in the non-cancer screening group (P < 0.0001). One hundred and seven (1.2%) lung cancers were diagnosed during PPP programme performance and another 382 cases (4.4%) in the 5-year follow-up, so the potential mean annual lung cancer detection rate is 0.77%.
CONCLUSIONS
Lung cancer screening programme offers a great potential for joint screening of lung cancer, CVD, diabetes and COPD.

Identifiants

pubmed: 31004154
pii: 5475452
doi: 10.1093/eurpub/ckz052
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1114-1117

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.

Auteurs

Marcin Ostrowski (M)

Department of Thoracic Surgery, Medical University of Gdańsk, Gdańsk, Poland.

Michał Marczyk (M)

Data Mining Division, Silesian University of Technology, Gliwice, Poland.
Department of Internal Medicine, Howard Hughes Medical Institute, Yale University, New Haven, CT 06519, USA.

Robert Dziedzic (R)

Department of Thoracic Surgery, Medical University of Gdańsk, Gdańsk, Poland.

Małgorzata Jelitto-Górska (M)

Department of Radiology, Medical University of Gdańsk, Gdańsk, Poland.

Tomasz Marjański (T)

Department of Thoracic Surgery, Medical University of Gdańsk, Gdańsk, Poland.

Sylwia Pisiak (S)

Department of Non-Invasive Cardiac Diagnostics, Medical University of Gdańsk, Gdańsk, Poland.

Tadeusz Jędrzejczyk (T)

Department of Public Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.

Joanna Polańska (J)

Data Mining Division, Silesian University of Technology, Gliwice, Poland.

Tomasz Zdrojewski (T)

Department of Preventive Medicine and Education, Medical University of Gdańsk, Gdańsk, Poland.

Bogdan Wojtyniak (B)

National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.

Witold Rzyman (W)

Department of Thoracic Surgery, Medical University of Gdańsk, Gdańsk, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH